CD73在肿瘤免疫微环境中的研究进展

Progress of CD73 in tumor immune microenvironment

胞外5'-核苷酸酶(CD73)不仅在多种实体肿瘤组织中高表达,而且与肿瘤的分期、治疗及肿瘤的预后有着密切关系。CD73可通过A2A受体、调控调节性T细胞、抑制炎症等多途径发挥广泛的免疫抑制活性。阻断CD73分子不仅能够有效激活抗肿瘤的免疫反应,而且能够显著提高程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抗体抑制肿瘤细胞的临床疗效。因此,CD73作为肿瘤微环境中新的免疫检查点分子,有可能成为继CTLA-4、PD-1/PD-L1后非常有前景的新免疫治疗靶点。

Extracellular 5'-nucleotidase(CD73)is not only highly expressed in a variety of solid tumor tissues,but also closely related to tumor stage,treatment and tumor prognosis.CD73 can exert a wide range of immunosuppressive effects through multiple pathways such as A2A receptor,regulation of regulatory T cells,and inhibition of inflammation.Blocking CD73 molecules can not only effectively activate anti-tumor immune responses,but also significantly improve the clinical efficacy of programmed death 1(PD-1)/programmed death ligand 1(PD-L1)antibodies.Thus,CD73,as a new immunological checkpoint molecule in the tumor microenvironment,may become a promising new immunotherapy target following CTLA4,PD-1/PD-L1.